1-3 of 3
Andreu Lapiedra
Close
Sort by
Journal Articles

Azacitidine In Compassionate Use: Response to Therapy, Survival, and Prognostic Factors In 200 Patients Diagnosed with MDS or AML

Regina García, Dunia de Miguel LLorente, Joan Bargay, Teresa Bernal, Jose Ramón González Porras, Mar Tormo, MD, PhD, Fernando Ramos, MD, Andreu Lapiedra, Jose Falantes, Blanca Xicoy, Guillermo F Sanz, MD, PhD, Benet Nomdedeu, MD, Salut Brunet, Joaquín Sánchez, Grupo Andaluz de Smd
Journal: Blood
Blood (2010) 116 (21): 2933.
https://doi.org/10.1182/blood.V116.21.2933.2933
Published: 2010
Journal Articles

Effectiveness of Various Dosage Regimens of Azacitidine In Patients with Myelodysplastic Syndromes: Safety and Efficacy Final Data From the Spanish Azacitidine Compassionate Use Registry

Regina García, Dunia De Miguel, Joan Bargay, Teresa Bernal, José Ramón Gonzalez, Mar Tormo, MD, PhD, Fernando Ramos, MD, Andreu Lapiedra, Jose Falantes, Blanca Xicoy, Guillermo F Sanz, MD, PhD, Benet Mondedeu, Salut Brunet, Joaquín Sanchez, Grupo Andaluz Smd
Journal: Blood
Blood (2010) 116 (21): 1853.
https://doi.org/10.1182/blood.V116.21.1853.1853
Published: 2010
Journal Articles

Azacitidine Is Effective in Patients with Intermediate-2 / High IPSS Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Regina Garcia, MD, José Ramón González, MD, PhD, Alicia Bailen, MD, Jose F Falantes, MD, Joaquin Sanchez, MD, Rafael F Duarte, Juan Besalduch, MD, Andreu Lapiedra, MD
Journal: Blood
Blood (2009) 114 (22): 4835.
https://doi.org/10.1182/blood.V114.22.4835.4835
Published: 2009